Osang Healthcare, a Leading IVD Company, Joins the Songdo Bio Cluster
With this leading IVD company’s emergence in Songdo International City, a massive impact is expected in terms of diversifying the industrial structure of the Songdo Bio Cluster, which is currently dominated by large corporations in biopharmaceutical production, and creating an industrial ecosystem.
On March 27, IFEZ Commissioner Kim Jin-yong and CEO Hong Seung-uk of Osang Healthcare signed a land-purchase contract to construct a research center in Songdo. Following the signing of this contract, Osang Healthcare will build an IVD research and manufacturing facility spanning 14,716 ㎡ of the Incheon Technopark Expansion Complex (Sr-13; Songdo-dong 178-5) in Songdo Zone 7. The project is scheduled to begin in 2024, with completion slated for 2026.
This agreement is significant in that Osang Healthcare selected the Songdo Bio Cluster as a base for its leap forward from an IVD medical device specialist to a bio-healthcare company. Osang Healthcare also anticipates synergy effects through cooperation with other companies in the Songdo Bio Cluster.
Location 178-5 Songdo-dong, Yeonsu-gu, Incheon
Start of Construction 2024
Completion Scheduled for 2026